StockPreacher.com issues Technical Trading Overview for Advanced Life Sciences Holdings Inc.

DALLAS, Oct. 1, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Advanced Life Sciences Holdings Inc. ADLS. The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Advanced Life Sciences Holdings Inc. ADLS should be of particular interest to other biopharmaceutical companies: Pfizer Inc. PFE, GlaxoSmithKline plc GSK, Sanofi-Aventis SNY and Merck & Co. Inc. MRK.

The full report is available at: http://www.stockpreacher.com/n/ADLS

Advanced Life Sciences Holdings Inc. (ADLS), a biopharmaceutical company, focuses on the discovery, development and commercialization of novel drugs in the areas of infectious disease, oncology and respiratory disease. Its lead candidate includes Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia. Cethromycin has also completed phase III clinical trials for the treatment of respiratory tract infections.

In the report, the analyst notes:

"ADLS is focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, oncology and respiratory disease. The Company's most advanced product candidate, Cethromycin, is a novel once-a-day oral antibiotic that completed two pivotal phase III clinical trials in community acquired pneumonia. The Company has an exclusive worldwide license (excluding Japan) from Abbott Laboratories to develop and commercialize Cethromycin (pending trade name Restanza(TM)). Cethromycin is also being developed as a bio-defense agent for use in the treatment of anthrax and other potential broad-spectrum medical countermeasures.

"The Company has three product candidates that are either in clinical development or are approved to begin clinical development, as well as six additional candidates in preclinical development for the treatment of respiratory distress caused by inflammation-related tissue damage and malignant melanoma. However, none of the Company's product candidates have been approved by the FDA or any comparable foreign agencies."

To read the entire report visit: http://www.stockpreacher.com/n/ADLS

See what investors are saying about these stocks at: http://www.stockhideout.com/

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.